Taro Pharmaceutical Industries (NYSE:TARO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report sent to investors on Saturday. The firm issued a strong-buy rating on the stock.

Separately, HC Wainwright lowered Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 price objective on the stock. in a research note on Thursday, January 18th.

Taro Pharmaceutical Industries Stock Performance

TARO opened at $42.40 on Friday. Taro Pharmaceutical Industries has a 52-week low of $24.69 and a 52-week high of $45.76. The firm has a market capitalization of $1.59 billion, a PE ratio of 34.75 and a beta of 0.61. The business’s 50-day simple moving average is $42.14 and its 200 day simple moving average is $40.03.

Taro Pharmaceutical Industries (NYSE:TARO) last released its earnings results on Thursday, January 25th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.26. The business had revenue of $157.15 million for the quarter, compared to analyst estimates of $154.90 million. Taro Pharmaceutical Industries had a return on equity of 3.26% and a net margin of 7.48%. On average, research analysts forecast that Taro Pharmaceutical Industries will post 1.38 earnings per share for the current year.

Hedge Funds Weigh In On Taro Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new position in shares of Taro Pharmaceutical Industries during the third quarter worth approximately $65,000. PenderFund Capital Management Ltd. bought a new position in shares of Taro Pharmaceutical Industries during the fourth quarter worth approximately $92,000. Strs Ohio increased its stake in shares of Taro Pharmaceutical Industries by 58.8% during the third quarter. Strs Ohio now owns 2,700 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Taro Pharmaceutical Industries during the fourth quarter worth approximately $105,000. Finally, SG Americas Securities LLC bought a new position in shares of Taro Pharmaceutical Industries during the third quarter worth approximately $141,000. Institutional investors own 91.40% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.